Literature DB >> 10447944

Novel A,B,E-ring-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities.

D Bom1, D P Curran, A J Chavan, S Kruszewski, S G Zimmer, K A Fraley, T G Burke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10447944     DOI： 10.1021/jm9902279

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  8 in total

1.  Semisynthesis, cytotoxic activity, and oral availability of new lipophilic 9-substituted camptothecin derivatives.

Authors:  Guillermo Rodriguez-Berna; Maria Jose Díaz Cabañas; Victor Mangas-Sanjuán; Marta Gonzalez-Alvarez; Isabel Gonzalez-Alvarez; Ibane Abasolo; Simó Schwartz; Marival Bermejo; Avelino Corma
Journal:  ACS Med Chem Lett       Date:  2013-05-28       Impact factor: 4.345

2.  Kinetics and mechanisms of activation of alpha-amino acid ester prodrugs of camptothecins.

Authors:  Lin Song; Robert Bevins; Bradley D Anderson
Journal:  J Med Chem       Date:  2006-07-13       Impact factor: 7.446

3.  An HPLC assay for the lipophilic camptothecin analog AR-67 carboxylate and lactone in human whole blood.

Authors:  Eleftheria Tsakalozou; Jamie Horn; Mark Leggas
Journal:  Biomed Chromatogr       Date:  2010-10       Impact factor: 1.902

4.  Novel topoisomerase I-targeting antitumor agents synthesized from the N,N,N-trimethylammonium derivative of ARC-111, 5H-2,3-dimethoxy-8,9-methylenedioxy-5-[(2-N,N,N-trimethylammonium)ethyl]dibenzo[c,h][1,6]naphthyridin-6-one iodide.

Authors:  Wei Feng; Mavurapu Satyanarayana; Yuan-Chin Tsai; Angela A Liu; Leroy F Liu; Edmond J LaVoie
Journal:  Eur J Med Chem       Date:  2009-02-20       Impact factor: 6.514

5.  A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies.

Authors:  Susanne M Arnold; John J Rinehart; Eleftheria Tsakalozou; John R Eckardt; Scott Z Fields; Brent J Shelton; Philip A DeSimone; Bryan K Kee; Jeffrey A Moscow; Markos Leggas
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

6.  11-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridine derivatives as novel topoisomerase I-targeting agents.

Authors:  Wei Feng; Mavurapu Satyanarayana; Yuan-Chin Tsai; Angela A Liu; Leroy F Liu; Edmond J LaVoie
Journal:  Bioorg Med Chem       Date:  2008-08-07       Impact factor: 3.641

7.  12-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridines as novel topoisomerase I-targeting antitumor agents.

Authors:  Wei Feng; Mavurapu Satyanarayana; Yuan-Chin Tsai; Angela A Liu; Leroy F Liu; Edmond J LaVoie
Journal:  Bioorg Med Chem       Date:  2009-02-20       Impact factor: 3.641

8.  The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.

Authors:  Lluis A Lopez-Barcons; Junhong Zhang; Gunching Siriwitayawan; Thomas G Burke; Roman Perez-Soler
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.